trending Market Intelligence /marketintelligence/en/news-insights/trending/s8bcxBmN1Z4kCQWaJ2tg6w2 content esgSubNav
In This List

Murad Chia Jei Biotechnology Q3 profit climbs YOY


Street Talk | Episode 94: Recessionary fears in '22 overblown, Fed could overtighten


Optimism abounds in Indian online video industry


2022 broadband forecast shifts to market share battle with intense competition


Expand Your Perspective: Innovation

Murad Chia Jei Biotechnology Q3 profit climbs YOY

Murad Chia Jei Biotechnology Co. Ltd. said its normalized net income for the third quarter was 13 Taiwan cents per share, an increase from 6 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$10.6 million, an increase from NT$5.2 million in the prior-year period.

The normalized profit margin rose to 5.6% from 3.3% in the year-earlier period.

Total revenue grew 19.2% on an annual basis to NT$190.5 million from NT$159.7 million, and total operating expenses totaled NT$161.8 million, compared with NT$160.6 million in the year-earlier period.

Reported net income rose 12.0% year over year to NT$7.4 million, or 9 cents per share, from NT$6.6 million, or 8 cents per share.

As of Nov. 16, US$1 was equivalent to NT$32.83.